Rxsight (US:RXST) — Company Overview, News & Financial Data

Rxsight logo
RXSTRxsight
Trade RXST now
Rxsight primary media

About Rxsight

Rxsight (NASDAQ:RXST) specializes in the innovative development of customizable intraocular lenses tailored to improve vision after cataract surgery. A standout in post-operative vision correction, their Light Adjustable Lens technology allows eye care professionals to adjust lens power after implantation, ensuring patients achieve optimal visual outcomes. Rxsight's endeavors aim to revolutionize patient experiences in eye care through groundbreaking adjustable lens technology, striving to meet the unique vision needs of individuals worldwide. The company's dedication is rooted in enhancing quality of life through superior visual acuity, moving beyond traditional approaches to address the dynamic nature of vision correction.

What is RXST known for?

Snapshot

Public US
Ownership
1997
Year founded
287
Employees
Aliso Viejo, United States
Head office
Loading Map...

Operations

All Locations
Aliso Viejo, US

Products and/or services of Rxsight

  • Light Adjustable Lens (LAL) technology allowing patients to customize and optimize their vision after cataract surgery.
  • LAL Delivery System, a device designed for the precise implantation of Light Adjustable Lenses.
  • UV Light Delivery Device, used to adjust the LAL post-implantation, enabling vision correction customization.
  • Advanced intraocular lenses (IOLs) designed for correcting presbyopia and astigmatism, enhancing overall visual outcomes.
  • Comprehensive patient education and support services aimed at improving understanding and management of vision correction options.
  • Research and development focused on next-generation vision correction solutions, harnessing innovative materials and optical designs.

Rxsight executive team

  • Dr. Ronald M. Kurtz M.D.President, CEO & Director
  • Dr. Ilya Goldshleger Ph.D.Chief Operating Officer
  • Mr. Eric J. WeinbergChief Business Development Officer
  • Mr. Mark WilterdingChief Financial Officer
  • Mr. Oliver MoravcevicVice President of Investor Relations
  • Mr. Jim SchindlerSenior VP & General Counsel
  • Mr. Scott GainesChief Customer Officer
  • Ms. Maureen O'ConnellExecutive VP of Clinical & Regulatory Affairs
  • Mr. Patrick CullenExecutive VP of Quality & Infrastructure Operations
  • Mr. Adam DasheExecutive Vice President of International

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.